Clinical trials: Thymic Cancer
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
To observe the efficacy of carbon ion radiotherapy combined with chemotherapy in the treatment of inoperable locally advanced or advanced (all visible lesions can be included in the radiation target area in this treatment)…
- Trial name
- NCT06186726
- Testing
- carbon ion radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
Thymic Epithelial Tumor, Radiotherapy Side Effect
Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection.
- Conditions
- Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
- Trial name
- NCT06311955
- Testing
- Carbon ion radiotherapy, combined with platinum-based regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
Thymus Epithelial Tumor, Proton Radiotherapy
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies.
- Conditions
- Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
- Trial name
- NCT06311968
- Testing
- Proton radiotherapy, combined platinum based chemotherapy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Jian Chen
Thymic Epithelial Tumor, Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer
- Trial name
- NCT05667948
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04432506
- Testing
- Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed or Metastatic Thymic Cancer, First-line Treatment
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
This study is a prospective, single arm phase II clinical trial ,aimed at exploring the efficacy and safety of the combination therapy of anti-PD-1 and VEGF bispecific antibody Ivonescimab combined with chemotherapy as first-line…
- Trial name
- iTHYM (NCT06750952)
- Testing
- Ivonescimab Combined With Chemotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Thymoma and Thymic Carcinoma, Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors.
- Conditions
- Thymoma and Thymic Carcinoma, Thymoma, Thymic Cancer, Thymic Epithelial Tumor
- Trial name
- NCT06692062
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Rongrong Zhou
Thymic Epithelial Tumor
RATT Vs. VATT for Early-stage TETs
This study is a prospective, multicenter, phase II randomized controlled trial. We plan to screen 100 eligible thymoma patients for robotic-assisted thoracoscopic thymectomy (RATT) or video-assisted thoracoscopic thymectomy…
- Trial name
- NCT06654830
- Testing
- RATT, VATT
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Thymic Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
- Trial name
- NCT05683886
- Testing
- KC1036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Thymic Carcinoma, Non-small Cell Lung Cancer
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint…
- Conditions
- Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
- Trial name
- NCT03583086
- Testing
- Vorolanib, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Background: The current standard of care for advanced lung cancer and cancers of the thymus consists primarily of chemotherapy treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Trial name
- NCT01306045
- Testing
- AZD6244, MK-2206, Lapatinib
- Where
- United States
- Volunteers
- 647 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Carcinoma, Thymic
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.
- Trial name
- NCT04321330
- Testing
- Atezolizumab
- Where
- 10 sites in China
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Thymic Carcinoma, Thymoma
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
This is a multicentric study. All patients with TET (thymic epithelial tumors) of any histological type will participate in the study.
- Trial name
- RELEVENT (NCT03921671)
- Testing
- Ramucirumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Claudia Proto
Thymic Epithelial Tumor, Teratoma
Establishing Prospective Mediastinal Tumor Database of PUMCH
This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors.
- Conditions
- Thymic Epithelial Tumor, Teratoma, Thymic Cyst, Retrosternal Goitre
- Trial name
- MTDPUMCH (NCT06421805)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Thymic Carcinoma
A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
This study will assess the safety and efficacy of the study drug KN046 in patients with advanced thymic carcinoma who progressed after prior treatment with immune checkpoint inhibitor therapy.
- Trial name
- NCT04925947
- Testing
- KN046
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Thymic Epithelial Tumor
Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
PURPOSE: To evaluate the efficacy and safety of Rivoceranib in patients with metastatic thymic epithelial tumors who developed resistance on first-line therapy.
- Trial name
- NCT06200233
- Testing
- Rivoceranib
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Thymic Epithelial Tumor, Thymic Carcinoma
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymoma, Thymoma and Thymic Carcinoma
- Trial name
- INTHYM (NCT06301945)
- Testing
- Artificial Intelligence Diagnostics, Recurrence Prediction Tool
- Where
- Netherlands
- Volunteers
- 1,020 people
- Sponsor
- Erasmus Medical Center